Insider Buying Activity at Axogen, Inc.
Kathy Johnson Weiler purchased 4,392 shares of Axogen, Inc. on June 24, 2026.
Key Points
- Kathy Johnson Weiler acquired 4,392 shares of Axogen, Inc. on June 24, 2026, marking a notable insider purchase.
- Axogen, Inc. trades on NasdaqCM with a market cap of $2.37 billion and a forward P/E of 61.08.
- Analysts from Canaccord Genuity and Wells Fargo have maintained buy ratings, with price targets up to $50.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Kathy Johnson Weiler, an insider at Axogen, Inc., purchased 4,392 shares of the company on June 24, 2026. This transaction was not part of a pre-planned trading program, indicating a discretionary buy from Weiler.
What Changed in Kathy Johnson Weiler's Axogen Position
Kathy Johnson Weiler's recent purchase of 4,392 shares of Axogen, Inc. wasn't tied to a pre-arranged plan, suggesting a personal investment decision. The details of the purchase price and total value weren't disclosed.
Other Institutional Activity in Axogen
Institutional investors have shown varied activity in Axogen. FIRST LIGHT ASSET MANAGEMENT, LLC reduced its holdings by 1,230,558 shares, bringing its total to 4,002,768 shares valued at approximately $132.6 million, a 23.5% decrease. BlackRock, Inc. added 151,414 shares, resulting in 3,870,851 shares worth about $128.2 million, a 4.1% increase. Morgan Stanley increased its position by 536,112 shares, now holding 3,122,982 shares valued at $103.5 million, marking a 20.7% growth. Vanguard Capital Management LLC opened a new position with 2,291,563 shares valued at $75.9 million. Arrowmark Colorado Holdings LLC boosted its stake by 441,157 shares, reaching a total of 1,915,439 shares worth $63.5 million, a 29.9% rise.
Axogen, Inc. Stock Down 12.7%
Shares of NasdaqCM:AXGN traded near $44.49 on Saturday. Axogen, Inc. has a market cap of $2.37 billion and a forward P/E ratio of 61.08. The stock's 52-week range spans from $10.20 to $46.00, with a 50-day moving average of $41.31 and a 200-day moving average of $30.96. The company maintains a healthy current ratio of 7.10 and a quick ratio of 4.99, with a debt-to-equity ratio of 8.43.
$AXGN stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Axogen, Inc. recorded revenue of $238.1 million, reflecting a 26.6% growth. However, the company posted a net margin of -13.21% and a return on equity of -17.96%. The next earnings report is expected on August 4, 2026.
Insider Buying and Selling at Axogen, Inc.
On June 24, 2026, several insiders, including Kathy Johnson Weiler, Joseph Tyndall, Paul Thomas, Amy McBride Wendell, William Burke, and John Johnson, each acquired 4,392 shares of Axogen. Paul Thomas purchased 5,579 shares. These transactions were not part of Rule 10b5-1 plans, indicating personal investment decisions.
Analysts Set New Price Targets
On April 29, 2026, Canaccord Genuity, Citizens, and Wells Fargo maintained their buy ratings on Axogen, with price targets of $50 and $48, respectively. HC Wainwright & Co. also maintained a buy rating with a $50 target. The consensus among analysts is a buy recommendation, with a mean target price of $50.78 based on 9 opinions.
About Axogen, Inc.
Axogen, Inc. is a healthcare company based in Alachua, Florida, specializing in medical devices for peripheral nerve regeneration and repair. The company offers a range of products, including the Avance Nerve Graft and Axoguard Nerve Protector, to hospitals and surgery centers worldwide. Led by CEO Ms. Lindsey Hartley, Axogen employs approximately 622 people.
Bottom Line
Insider buying at Axogen, Inc. signals potential confidence in the company's future prospects. The stock's recent trading activity and analyst ratings suggest that investors are keeping a close watch on its performance. As always, it's important to remember that insider transactions are historical data and may not reflect future trends.
Get Axogen, Inc. alerts
New 13F filings, insider trades, and analyst moves on $AXGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.